Acute Respiratory Distress Syndrome and COVID-19: A Literature Review
Musaddique Hussain,Shahzada Khurram Syed,Mobeen Fatima,Saira Shaukat,Malik Saadullah,Ali M Alqahtani,Taha Alqahtani,Talha Bin Emran,Ali H Alamri,Muhammad Qasim Barkat,Ximei Wu
DOI: https://doi.org/10.2147/JIR.S334043
IF: 4.5
2021-01-01
Journal of Inflammation Research
Abstract:Acute respiratory distress syndrome (ARDS) is an overwhelming inflammatory disorder of the lung due to direct and indirect insults to the lungs. ARDS is characterized by increased vascular permeability, protein-rich edema, diffuse alveolar infiltrate, and loss of aerated lung tissue, leading to decreased lung compliance, tachypnea, and severe hypoxemia. COVID-19 is generally associated with ARDS, and it has gained prime importance since it started. The mortality rate is alarmingly high in COVID-19-related ARDS patients regardless of advances in mechanical ventilation. Several pharmacological agents, including corticosteroids, nitric oxide, neuromuscular blocker, anti-TNF, statins, and exogenous surfactant, have been studied and some are under investigation, like ketoconazole, lisofylline, N-acetylcysteine, prostaglandins, prostacyclin, and fish oil. The purpose of this review is to appraise the understanding of the pathophysiology of ARDS, biomarkers, and clinical trials of of ARDS and COVID-19-related ARDS.